|
|
|
|
|
Enoxaparin
drug data and news
Enoxaparin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Enoxaparin | ||
| Brand Names/Synonyms | Enoxaparin; Enoxaparin Sodium; Heparin; Heparin Sodium; Heparin Sodium Salt; Lovenox; Lovenox Hp; Low Molecular Weight Heparin Sodium | ||
| Indication | For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of Enoxaparin in combination with antithrombin III (Enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of Enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. | ||
| Mechanism Of Action | The mechanism of action of Enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of Enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. | ||
| Enoxaparin News (When available) |
Wockhardt wins USFDA nod for Ranitidine OTC version Feb 27, 2006 Wockhardt receives US FDA approval for Ranitidine OTC version Feb 27, 2006 New US tonic for Wockhardt Feb 27, 2006 Indices firm ahead of tomorrow's budget announcement Feb 27, 2006 Misdosing of Medications Prompts Most Poison Calls About Young ... Mar 1, 2006 Common practice of prescribing H2 blockers to treat acid reflux in ... Feb 24, 2006 Class-action suit filed against Omnicare Feb 6, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk Feb 9, 2006 The Gita Mathai Column:Ooch, my stomach hurts Feb 14, 2006 Omnicare Shares Skid on Downgrade Sparked by Raid Feb 5, 2006 Shareholder Class Action Filed Against Omnicare, Inc. by the Law ... Feb 13, 2006 Acid Reflux: Is the Medication Worse Than the Condition? FLAVORx ... 09 Feb 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk 09 Feb 2006 Common Reflux Treatment Linked to Life Threatening Bowel Infection ... 09 Feb 2006 Probe News Punishes Omnicare Jan 17, 2006 Class-action suit filed against Omnicare Feb 6, 2006 Omnicare Shares Skid on Downgrade Sparked by Raid Feb 5, 2006 Omnicare subpoenaed in generic drug probe Jan 16, 2006 It's Enough to Give Him an Ulcer! Jan 20, 2006 Update 1-Omnicare says gets subpoena from US Attorney Jan 13, 2006 Omnicare drug 'relationships' come under federal scrutiny Jan 13, 2006 Business digest Jan 17, 2006 Dr. Reddy's Reports Q3 FY06 Revenue of Rs. 5,902 Million; YoY ... Jan 24, 2006 City Councilman resigns Jan 12, 2006 Ranitidine Zeptag beats Everball 109-97 Dec 2, 2005 Booster shot Dec 4, 2005 Holiday heartburn Dec 6, 2005 Horse Racing Authority amends drug rules Nov 14, 2005 Kentucky Horse Racing Authority modifies drug rules Nov 14, 2005 Kentucky Horse Racing Authority Gives Final Approval to Drug ... Nov 15, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Book Excerpt: Laminitis Nov 16, 2005 Holidays Present Challenges for Children With GERD Nov 23, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 | ||
| Dosage Forms | Solution for subcutaneous injection | ||
| Drug_Category | Fibrinolytic Agents; Anticoagulants; Heparins; ATC:B01AB05 | ||
| Absorption | ~100% following subcutaneous injection | ||
| Interactions |
-->Interactions for Enoxaparin: Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring. | ||
| Toxicity | Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-[5-acetylamino-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)-3-sulfoamino-4-sulfooxy-tetrahydropyran-2-yl]oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2-carboxylicacid | ||
| Chemical Formula | (C26H40N2O36S5)n | ||
| Molecular Weight | 3500-5500 g/mol (average 4500 g/mol) | ||
| Smiles String | CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | > 200 mg/mL | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 4.5 hours | ||
| Protein Binding [%] | 80% bound-albumin | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Enoxaparin.html http://www.rxlist.com/cgi/generic3/lovenox.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00068 | ||
| CAS Registry Number | 9005-49-6 | ||
| KEGG Compound ID | C00374 | ||
| PubChem ID | SID:7979167 | ||
| PharmGKB ID | PA449463 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2242692 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |